Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | FPR1 | P21462 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784642 | 0.93 | TRPV1 (0.46) | TRPV1KMT2AMALT1LMNAMEN1 | |
| SCHEMBL785926 | 0.90 | TRPV1 (0.42) | TRPV1FPR1FPR2KMT2ALMNA | |
| SCHEMBL785738 | 0.90 | ALDH1A1 (0.45) | TRPV1KMT2ALMNAMEN1MAPT | |
| SCHEMBL784732 | 0.87 | MALT1 (0.41) | TRPV1FPR1FPR2KMT2AMALT1 | |
| SCHEMBL785701 | 0.87 | TAS1R3 (0.41) | TRPV1FPR1FPR2KMT2ALMNA | |
| SCHEMBL785726 | 0.87 | TAS1R3 (0.41) | TRPV1FPR1FPR2KMT2ALMNA | |
| SCHEMBL784989 | 0.87 | PRMT3 (0.40) | TRPV1FPR1FPR2KMT2AMALT1 | |
| SCHEMBL785131 | 0.87 | TRPV1 (0.42) | TRPV1KMT2ALMNAMEN1MAPT | |
| SCHEMBL785838 | 0.86 | TRPV1 (0.44) | TRPV1FPR1FPR2KMT2AMALT1 | |
| SCHEMBL785460 | 0.86 | TRPV1 (0.41) | TRPV1FPR1FPR2KMT2AMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TRPV1 21/4885FPR1 79/4885FPR2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.